DRTS

Alpha Tau Medical Ltd.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $14.77
52-Week Range: $3.43 – $15.79
Market Cap: $1.38B
P/E (TTM): —
EPS (TTM): -1.04
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 31.22
PEG Ratio: —
Return on Equity: -141.68%
Return on Assets: -25.71%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 11.09
Debt/Equity: 0.34
Total Debt: $15.15M
Free Cash Flow: $-20.26M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.28B

DRTS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$20.89M	$26.42M	$27.02M	$32.06M
Selling, General & Admin	$11.25M	$9.26M	$9.02M	$10.22M
Operating Expenses	$32.14M	$35.68M	$36.04M	$42.29M
Operating Income	-$32.14M	-$35.68M	-$36.04M	-$42.29M
EBITDA	-$32.76M	-$27.99M	-$30.34M	-$40.93M
Pretax Income	-$33.74M	-$29.14M	-$31.74M	-$42.51M
Income Tax	$20.00K	$16.00K	$6.00K	$121.00K
Net Income	-$33.76M	-$29.16M	-$31.75M	-$42.63M
Diluted EPS	-0.53	-0.42	-0.45	-0.53
Diluted Shares	63.53M	69.38M	69.93M	80.58M

DRTS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.84M	$12.66M	$13.72M	$12.20M
Receivables	$313.00K	$344.00K	$332.00K	$336.00K
Current Assets	$106.48M	$85.76M	$64.23M	$78.30M
Total Assets	$120.15M	$107.39M	$86.20M	$105.65M
Current Liabilities	$4.34M	$7.10M	$8.68M	$10.51M
Long-Term Debt	—	$5.61M	$5.56M	$6.35M
Total Debt	$5.19M	$13.28M	$12.54M	$13.73M
Total Liabilities	$14.49M	$22.91M	$23.54M	$28.55M
Retained Earnings	-$86.60M	-$115.76M	-$147.51M	-$190.14M
Shareholders' Equity	$105.66M	$84.47M	$62.67M	$77.10M
Working Capital	$102.14M	$78.65M	$55.55M	$67.79M

DRTS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.88M	-$17.96M	-$19.78M	-$26.68M
Capital Expenditure	-$904.00K	-$6.40M	-$2.24M	-$6.08M
Free Cash Flow	-$24.78M	-$24.36M	-$22.02M	-$32.76M
Depreciation & Amortisation	$979.00K	$1.07M	$1.10M	$1.23M
Stock-Based Compensation	$6.75M	$7.93M	$9.92M	$10.62M
Investing Cash Flow	-$89.94M	$18.68M	$20.77M	-$20.59M
Financing Cash Flow	$96.91M	$5.30M	$25.00K	$45.77M
Net Change in Cash	-$16.91M	$6.02M	$1.01M	-$1.50M

DRTS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.17M	$7.01M	$8.31M	$9.58M	$10.97M	$9.91M
Selling, General & Admin	$2.14M	$2.64M	$2.42M	$3.03M	$2.34M	$3.88M
Operating Expenses	$9.31M	$9.65M	$10.73M	$12.60M	$13.31M	$13.78M
Operating Income	-$9.31M	-$9.65M	-$10.73M	-$12.60M	-$13.31M	-$13.78M
EBITDA	-$9.31M	-$9.18M	-$11.20M	-$12.47M	-$13.31M	-$55.05M
Pretax Income	-$8.59M	-$10.05M	-$11.69M	-$12.17M	-$22.95M	-$45.58M
Income Tax	$99.00K	$65.00K	-$8.00K	-$35.00K	-$11.00K	$229.00K
Net Income	-$8.69M	-$10.11M	-$11.69M	-$12.14M	-$22.94M	-$45.81M
Diluted EPS	-0.12	—	—	—	-0.26	—
Diluted Shares	70.45M	—	—	—	89.71M	—

DRTS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.02M	$11.70M	$3.33M	$12.20M	$4.64M	$22.99M
Receivables	$1.94M	$2.52M	$1.22M	$336.00K	$1.12M	$2.06M
Current Assets	$56.79M	$85.78M	$77.10M	$78.30M	$81.35M	$106.83M
Total Assets	$80.93M	$110.95M	$104.69M	$105.65M	$108.77M	$134.25M
Current Liabilities	$9.77M	$8.16M	$9.14M	$10.51M	$10.45M	$9.63M
Long-Term Debt	$5.47M	$6.03M	$6.15M	$6.35M	$6.40M	$6.80M
Total Debt	$12.29M	$13.31M	$13.50M	$13.73M	$14.34M	$15.15M
Total Liabilities	$24.60M	$24.33M	$27.11M	$28.55M	$39.42M	$90.19M
Retained Earnings	-$156.20M	-$166.31M	-$178.00M	-$190.14M	-$213.07M	-$258.89M
Shareholders' Equity	$56.33M	$86.62M	$77.58M	$77.10M	$69.35M	$44.05M
Working Capital	$47.02M	$77.62M	$67.96M	$67.79M	$70.90M	$97.20M
Net Debt	$453.00K	—	$2.82M	—	$1.77M	—

Market Snapshot

About

Alpha Tau Medical Ltd. is an Israeli medical device company developing innovative cancer radiation therapy solutions. The company's Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology delivers alpha radiation directly to solid tumors through radioactive seeds. Alpha Tau's approach aims to destroy tumors while minimizing damage to surrounding healthy tissue. The technology is being studied for treating various solid tumor types including skin, head and neck, breast, and pancreatic cancers. The company is conducting clinical trials and pursuing regulatory approvals in multiple markets.